Singapore Association of Pharmaceutical Industries’ Post

SAPI President Hwee Tee Poh and Vice President Yeoh Ying Ying recently participated in two panels as part of the Singapore Clinical Research Institute (SCRI) Clinical Trials Symposium, an event that brought professionals in clinical research around the world together, to showcase the value proposition of clinical trials in Singapore. In the first day’s plenary session, Hwee Tee, alongside other esteemed panellists such as Prof Kenneth Mak, Adj A/Prof Danny Soon, Mr Adrian Yap, A/Prof David SP Tan and Dr Daph Gardner, explored the value of clinical trials from the patient, healthcare professionals and industry perspectives, covering topics on access to new treatments, evidence-based practice and innovation. On the second day, Ying Ying moderated a panel including Prof C. Michael Gibson, M.S., M.D., Ms Mingshi Koh and Prof Khung Keong Yeo to discuss innovations in data-driven research, and how data can unlock different possibilities for research and its impact on patients. Thank you to all panellists and SCRI for the engaging and enriching event! Through important dialogue sessions such as this and collaborative efforts, we can further strengthen Singapore's position as a leading clinical trial hub. SAPI is committed to working with all stakeholders to streamline processes, enhance support systems, and foster innovation, ensuring patients receive early access to cutting-edge treatments. We deeply value SCRI's longstanding partnership and look forward to our continued collaboration in this vital mission. Learn more about Hwee Tee and Ying Ying’s key takeaways from the sessions in the slides below. 📷 Consortium for Clinical Research and Innovation, Singapore (CRIS) #SCRIClinicalTrialsSymposium2024 #SAPI #ClinicalTrials #ClinicalResearch

To view or add a comment, sign in

Explore topics